Here are the a few companies, what they do, as well as when GV invested:
Spero Therapeutics, a biopharmaceutical company creating treatments for bacterial infections, began trading on the Nasdaq last fall as well as includes a current market cap of $204.8 million.
GV led its Series C in March 2017 as well as its stake is actually at This kind of point worth $15.79 million, according to FactSet.
Arsanis, which is actually working on antibody immunotherapies for infectious diseases, went public in November of last year as well as includes a market cap of $327.2 million. GV invested in its Series D in April 2017 as well as its stake is actually worth $10.62 million, according to FactSet.
Arcus Bioscience, which develops cancer immunotherapies, went public in March as well as includes a market cap of $657 million.
GV first invested in Arcus’ Series B in 2016 as well as again in its Series C in 2017, as well as its stake is actually worth $80.9 million, according to FactSet.
ARMO Biosciences fights cancer through immunotherapy. This kind of went public in January 2018 includes a market cap of $1.1 billion. GV invested in its Series C as well as its Series C-1 in 2016 as well as 2017 respectively, as well as its stake is actually currently worth $45.14 million.
Denali Therapeutics creates therapies for neurodegenerative diseases like Alzheimer’s as well as Parkinson’s as well as went public in December 2017 as well as currently includes a market cap of $1.86 billion.
There’s a not bad chance 2018 will bring more excitement: Nasdaq’s head of healthcare listings recently predicted that will biotech M&A will be hot This kind of year as well as that will we could see 30+ total biotech IPOs.
GV portfolio company 23andMe is actually supposed to file before the end of the year.